ABSTRACT. We describe a case of sex reassignment surgery and the subsequent development of lupus erythematosus tumidus (LET). LET is characterized clinically by erythematous, succulent, edematous, non-scarring plaques in sun-exposed areas. Results of histological examination show perivascular and periadnexal lymphocytic infiltration and interstitial mucin deposition. This report emphasizes that environmental triggers, including prolonged exposure to significant doses of estrogens as part of sex reassignment surgery, may lead to the development of lupus in a non-predisposed individual. (First Release August 1 2007; J Rheumatol 2007;34:1938–40)

CASE REPORT

A 40-year-old individual who had undergone sex reassignment surgery (male to female) was referred to the Lupus Clinic. Recently, she had developed a diffuse rash on the face, chest, and back, and was diagnosed as having cutaneous lupus. During the following months, she complained of muscle weakness, symmetric joint pain involving the knees and the hands, chest pain that was exacerbated by deep inspiration, and mood swings.

The history included sex reassignment surgery and silicone augmentation mammoplasty in 2000. As preparation for the operation, she was treated with estradiol ethinylestradiol, conjugated estrogens, and cyproterone acetate/ethinylestradiol (combination antiandrogen and estrogen). Since reassignment surgery she had been taking a continuous regimen of estradiol valerate. For the recent symptoms, she received monthly intramuscular betamethasone.

The skin biopsy revealed mild interface vacuolar changes and dense lymphocytic infiltrate with a perivascular disposition and differing degrees of mucin deposition is common.

The etiology of systemic lupus erythematosus (SLE) is multifactorial: intrinsic (genetic predisposition) and extrinsic (environmental) triggers contribute to disease progression and pathogenesis. The intrinsic abnormalities are complicated, with diverse genetic polymorphisms described in different ethnic groups, strongly suggesting that the actual pathology underlying the immunologic disarray might not be the same for each patient. Potential causes for the female predilection for SLE include the effects of estrogen and its hydroxylation, decreased androgen levels, hyperprolactinemia, and differences in gonadotropin-releasing hormone signaling. Environmental exposures include drugs capable of modulating immune responses such as exogenous estrogens. The amount and timing of exposure to different environmental factors may play a significant and complex role in the onset of disease.

We describe the first report of a man who underwent sex reassignment surgery and developed lupus erythematosus tumidus (LET). Sontheimer’s classification includes lupus tumidus as a specific lupus erythematosus skin disease, a form of chronic cutaneous lupus erythematosus, with urticarial plaque morphology. The clinical presentation usually involved erythematous, edematous plaques located on the face, chest, back, or extremities, related to sun exposure. A dermal lymphocytic infiltrate with a perivascular disposition and differing degrees of mucin deposition is common.

Key Indexing Terms: SEX REASSIGNMENT SURGERY ESTROGEN SYSTEMIC LUPUS ERYTHEMATOSUS LUPUS ERYTHEMATOSUS TUMIDUS SILICONE AUGMENTATION MAMMOPLASTY
DISCUSSION

This is the first reported case of LET in a patient following sex reassignment surgery (male to female) treated with estrogens and antiandrogens. The definite diagnosis of SLE is based on the American College of Rheumatology guidelines requiring 4 of 11 criteria. The combination of rash (biopsy-proven tumidus LE), arthritis, and serositis is highly suspicious for SLE. However, with negative serology (ANA and anti-DNA), the diagnosis remains that of cutaneous LE or SLE-like disease.

LET is characterized clinically by erythematous, succulent, edematous, nonscarring plaques in sun-exposed areas. Results of histological examination show perivascular and periadnexal lymphocytic infiltration and interstitial mucin deposition. LET has been documented rarely in the literature, and its clinical importance has not been fully appreciated. The onset of the disease, in 40 patients followed for 14 years, clustered in summer because of sun exposure, and 70% of the patients showed a remarkable photosensitivity confirmed by results of provocative phototesting. A complete resolution of the skin lesions was seen after systemic therapy with antimalarials. In 10% of the patients, ANA were detected; however, there was no evidence of underlying systemic involvement in any of the patients. A key controversial question in LET is the histologic picture. A lymphocytic perivascular and periadnexal infiltrate, dermal mucin deposition, and often negative direct immunofluorescence test are typical. Nevertheless, the possible existence of minimal epidermal and dermal–epidermal junction changes was described.

The effect of estrogens on the immune system is significant. Not only natural hormones, but also endocrine disruptors, such as environmental estrogens, may act in conjunction with other factors to override immune tolerance to self-antigens. In the B cell compartment, both prolactin and estrogen are immunomodulators that affect maturation, selection, and antibody secretion. Their influence may be based on their capacity to allow autoreactive B cells to escape the normal

---

Table 1. The patient’s hormonal profile.

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH</td>
<td>3.85 mIU/ml</td>
<td>0.6–19 mIU/ml (luteal phase); 2–12 mIU/ml (male)</td>
</tr>
<tr>
<td>FSH</td>
<td>573 mIU/ml</td>
<td>18–153 mIU/ml (postmenopausal); 2–12 mIU/ml (male)</td>
</tr>
<tr>
<td>E2</td>
<td>&lt; 200</td>
<td>70–220 pmol/L (female); &lt; 180 pmol/l (male)</td>
</tr>
<tr>
<td>Testosterone</td>
<td>0.15 nmol/l</td>
<td>0.21–2.98 (female); 9.36–37.1 (male)</td>
</tr>
<tr>
<td>Cortisol</td>
<td>474 µg/dl</td>
<td>5–25 mg/dl</td>
</tr>
<tr>
<td>Prolactin</td>
<td>139 ng/ml</td>
<td>1.9–25.9 ng/ml (female); 1.6–23.0 ng/ml (male)</td>
</tr>
</tbody>
</table>

FSH: follicle-stimulating hormone; LH: luteinizing hormone; E2: estradiol.

---

Figure 1. Skin biopsy results from the patient. A. Scanning magnification reveals superficial and deep perivascular and periadnexal lymphocytic infiltration (H&E, original magnification ×40). B. Higher magnification reveals vacuolar degeneration at the dermoepidermal junction and mucin deposits between the collagen bundles (H&E, original magnification ×200).

Figure 2. Alcian blue stain for mucin revealed granular fibrillary material between collagen bundles (H&E, original magnification ×600).
mechanisms of tolerance and to accumulate in sufficient numbers to cause clinically apparent disease. Estrogen leads to the survival and activation of autoreactive B cells, by eliciting T cell-independent autoreactive marginal-zone B cells.8

Hyper-estrogenic states can affect SLE disease activity. Ingestion of oral contraceptives high in estrogen content and hormone replacement therapy for postmenopausal women may be associated with mild disease flare.9 Ovarian stimulation may lead to the induction of SLE.10

Female patients with SLE have lower plasma androgen levels than their healthy counterparts. The closest natural hormonal counterpart in a male patient would be Klinefelter’s syndrome, where low androgen levels are detected and a few case reports describe concomitant SLE.11

The patient’s hormonal profile at the development of lupus was equivalent to a woman during the menopausal period, with a very elevated FSH level. The low testosterone level was probably a result of castration and feminizing hormone therapy. In addition, while maintaining female hormone therapy, she had elevated levels of prolactin. Hyperprolactinemia has been reported in 20%–30% of patients with lupus. Moreover, prolactin has a direct effect on B cells enhancing autoimmunity. Importantly, cutaneous lupus developed in this case in a female hormonal milieu, one that is more optimal for B cell dysregulation.12

Anecdotal reports have appeared of individuals where autoimmune diseases developed after mammary augmentation with silicone gel-filled elastomer envelope-type prostheses. However, many large studies and metaanalyses did not provide significant statistical evidence for any correlation between the development of SLE and silicone augmentation mammoplasty. We have described an array of autoantibodies found in autoimmune diseases in individuals following silicone mammoplasty. Although not proven, the fact that our patient underwent silicone mammoplasty could be yet another environmental trigger in the development of SLE.

This is the first reported case of sex reassignment surgery and the subsequent development of cutaneous lupus. Although a genetic component was not sought, and SLE can appear in men, we present this first report to emphasize that environmental triggers including high doses of estrogens as part of sex reassignment surgery may lead to the development of lupus in a nonpredisposed individual.

REFERENCES